AstraZeneca completes sale of Aptium Oncology assets

Friday, 6 July 2012

AstraZeneca today announced that it has completed the previously indicated sale of the assets of its subsidiary, Aptium Oncology.

Aptium Oncology provided outpatient oncology management and consulting services in the US, managing outpatient cancer centres in affiliation with five hospitals in California, Florida, New Jersey and New York. The subsidiary generated revenues of $224 million in 2011, and of $43m in 2012 up until completion of the disposals.

As indicated in the 2011 annual report, Aptium Oncology was a non-core business and AstraZeneca had decided to transfer ownership of these cancer centres to each of the hospitals. These agreements have been reached over the last several months and the disposals have now been completed.

The completion of the disposals of Aptium Oncology assets does not impact on AstraZeneca’s previously stated guidance for 2012.

CONTACTS

Media Enquiries

Esra Erkal-Paler +44 20 7604 8030
Sarah Lindgreen +44 20 7604 8033

Investor Enquiries UK

James Ward-Lilley +44 20 7604 8122 mob: +44 7785 432613
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Nicklas Westerholm +44 20 7604 8124 mob: +44 7585 404950

Investor Enquiries US

Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043